Trials / Terminated
TerminatedNCT00198172
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (planned)
- Sponsor
- Indiana University School of Medicine · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study E39897.
Detailed description
To determine the feasibility and toxicity of combining epirubicin to fixed does cisplatin; to determine the partial and complete response rate and duration of remission; to determine the toxicity; to ascertain the potential for greater than 12 month continuous disease-free survival and, therefore, potential curability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin plus Epirubicin |
Timeline
- Start date
- 2000-10-01
- Completion
- 2007-03-01
- First posted
- 2005-09-20
- Last updated
- 2014-06-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00198172. Inclusion in this directory is not an endorsement.